Abstract
Activation of angiogenesis is a necessary condition for tumor growth and metastatic dissemination of solid tumors. Numerous anti-angiogenic agents for the treatment of melanoma are currently in clinical trials or in development. A number of early-phase clinical trials have been completed and studies investigating combinations of targeted agents or combining treatment with chemotherapy are ongoing. The present review focuses on the most recent developments in the field of angiogenesis targeting in melanoma and provides a brief overview of available clinical data and future directions.
| Original language | English |
|---|---|
| Pages (from-to) | 237-248 |
| Number of pages | 12 |
| Journal | Expert Review of Dermatology |
| Volume | 4 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 14 Sept 2009 |
Keywords
- Angiogenesis
- Anti-angiogenic agent
- Melanoma
- Monoclonal antobody
- New treatment strategies
- Protein kinase inhibitor
